Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 4, 2008, Pages 365-374

  Hedenus, M ^c   Nasman P ^a   Liwing, J ^b  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b Roche AB   (Sweden)

^c SUNDSVALL HOSPITAL   (Sweden)

Author keywords

Anaemia, cancer, cost effectiveness, erythropoietin, IV iron, lymphoproliferative malignancies

Indexed keywords

FERRIC HYDROXIDE SUCROSE; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; IRON DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON THERAPY; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; SWEDEN; TREATMENT RESPONSE; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; ECONOMICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NEOPLASM; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

AGED; AGED, 80 AND OVER; ANEMIA; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON COMPOUNDS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; NEOPLASMS; SWEDEN;

EID: 49849091822     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00924.x     Document Type: Article

References (38)

1. Rizzo JD, Lichtin AE, Woolf SH et al. (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood, 100, 2303-2320.
2. Bokemeyer C, Aapro MS, Courdi A et al. (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. European Journal of Cancer, 43, 258-270.
3. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: cancer- and treatment- related anemia (2008) Version 1. Available at: http://www.nccn.org/professionals/physician-gls/PDF/anemia.pdf (accessed 14 March 2008).
4. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A (2005) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive metaanalysis. Journal of the National Cancer Institute, 97, 489-498.
5. Bohlius J, Weingart O, Trelle S, Engert A (2006) Cancer-related anemia and recombinant human erythropoietin - an updated overview. Nature Clinical Practice Oncology, 3, 152-164.
6. Hedenus M, Vansteenkiste J, Kotasek D, Austin M, Amado RG (2005) Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. Journal of Clinical Oncology, 23, 6941-6948.
7. Aapro M, Coiffier B, Dunst J,Ö sterborg A, BurgerH-U (2006) Effect of treatment with epoetin beta on shortterm tumour progression and survival in anaemic patients with cancer: a meta-analysis. British Journal of Cancer, 95, 1467-1473.
8. Ludwig H, Van Belle S, Barrett-Lee P et al. (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. European Journal of Cancer, 40, 2293-2306.
9. Mano M, Butzberger P, Reid A, Rodger A, Soutar R, Wesh J (2005) Current role of erythropoietin in the management of patients with haematological and solid malignancies. Cancer Therapy, 3, 41-56.
10. Roy CN, Andrews NC (2005) Anemia of inflammation: the hepcidin link. Current Opinion in Hematology, 12, 107-111.
11. Henry DH (1998) Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPÓ Oncologist, 3, 275-278.
12. Nemeth E, Ganz T (2006) Regulation of iron metabolism by hepcidin. Annual Review of Nutrition, 26, 323-342.
13. Glaspy J, Cavill I (1999) Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology (Williston Park), 13, 461-473.
14. Glaspy J, Beguin Y (2005) Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon). Oncology, 69(Suppl. 2), 8-16.
15. Cavill I, Auerbach M, Bailie GR et al. (2006) Iron and the anemia of chronic disease: a review and strategic recommendations. Current Medical Research and Opinion, 22, 731-737.
16. Macdougall IC (1999) Strategies for iron supplementation: oral versus intravenous. Kidney International Supplement, 69, S61-S66.
17. Locatelli F, Aljama P, Bárány P et al. (2004) Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrology, Dialysis, Transplantation, 19 (Suppl. 2), ii1-47.
18. Hedenus M, Birgega°rd G, Näsman P et al. (2007) Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia, 21, 627-632.
19. Auerbach M, Ballard H, Trout JR et al. (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, openlabel, randomized trial. Journal of Clinical Oncology, 22, 1301-1307.
20. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR (2007) Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist, 12, 231-242.
21. Henriksson F, Fredrikson S, Masterman T, Jönsson B (2001) Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. European Journal of Neurology, 8, 27-35.
22. Briggs AH, Wonderling DE, Mooney CZ (1997) Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Economics, 6, 327-340.
23. Glenngård AH, Persson U, Söderman C (2005) Costs associated with blood transfusions in Sweden - the societal cost of autologous, allogeneic and perioperative RBC transfusion. Transfusion Medicine, 15, 295-306.
24. Agrawal S, Davidson N, Walker M, Gibson S, Lim C, Morgan CL, Cowell W (2006) Assessing the total costs of blood delivery to hospital oncology and haematology patients. Current Medical Research and Opinion, 22, 1903-1909.
25. Crémieux PY, Barrett B, Anderson K, Slavin MB (2000) Cost of outpatient blood transfusion in cancer patients. Journal of Clinical Oncology, 18, 2755-2761.
26. Dunn A, Carter J, Carter H (2003) Anemia at the end of life: prevalence, significance, and causes in patients receiving palliative care. Journal of Pain and Symptom Management, 26, 1132-1139.
27. Eisenstaedt R, Penninx BW, Woodman RC (2006) Anemia in the elderly: current understanding and emerging concepts. Blood Reviews, 20, 213-226.
28. Weiss G, Goodnough LT (2005) Anemia of chronic disease. The New England Journal of Medicine, 352, 1011-1023.
29. Wilson J, Yao GL, Raftery J et al. (2007) A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technology Assessment, 11, 1-202.
30. Cornes P, Coiffier B, Zambrowski JJ (2007) Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option. Current Medical Research and Opinion, 23, 357-368.
31. Crémieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB (1999) Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics, 16, 459-472.
32. Szucs TD, Boogaerts M, Coiffier B, Kainz C (2001) Cost-effectiveness of epoetin beta in the management of cancer-related anaemia. Presented at the 6th Annual Congress of the European Haematology Association, Frankfurt, Germany 21-24 June 2001. The Hematology Journal, 2 (Suppl. 1), 67 (Abstract 192).
33. Borget I, Tilleul P, Baud M, Joly AC, Daguenel A, Chouaid C (2006) Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: a Markov analysis. Lung Cancer, 51, 369-376.
34. Österborg A, Brandberg Y, Molostova V et al. (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. Journal of Clinical Oncology, 20, 2486-2494.
35. Boogaerts M, Coiffier B, Kainz C, Epoetin beta QOL Working Group (2003) Impact of epoetin beta on quality of life in patients with malignant disease. British Journal of Cancer, 88, 988-995.
36. Hedenus M, Adriansson M, San Miguel J et al. (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. British Journal of Haematology, 122, 394-403.
37. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double- blind, placebo-controlled trial. Journal of Clinical Oncology, 19, 2865-2874.
38. de Castro J, Ordóñez A, Isla D, Sánchez A, Arrivi A, Manzano JL, Barón MG (2007) Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinumbased chemotherapy: results of the NeoPrevent study. Cancer Chemotherapy and Pharmacology, 59, 35-42.